Core Viewpoint - The company Chuangshi Technology (300941.SZ) is facing significant challenges due to legal issues involving its controlling shareholder Zhang Gengsheng, who has been placed under detention following bribery allegations. This situation raises concerns about the company's governance and operational stability. Group 1: Legal Issues - Zhang Gengsheng, the controlling shareholder and former chairman of Chuangshi Technology, has been subjected to detention measures by the Zouping Municipal Supervisory Committee due to bribery allegations [1][3] - Zhang resigned from his positions as director and chairman on May 17 of this year and is currently not serving in any executive role within the company [1][2] - The company has received a notice regarding the ongoing legal proceedings but is currently unaware of the developments or conclusions related to these matters [1] Group 2: Financial Performance - Chuangshi Technology has reported a decline in revenue for four consecutive years since 2021, with a significant drop in net profit since 2022 [4] - For the first three quarters of this year, the company achieved a revenue of 156 million yuan, representing a year-on-year increase of 15.45%, while the net profit attributable to shareholders decreased by 45.84% to 15.32 million yuan [4] - The company's internal control audit report has received a non-standard opinion from the accounting firm, indicating potential governance issues [4] Group 3: Business Overview - Chuangshi Technology specializes in providing electronic payment solutions, industry-specific applications, and digital marketing services to merchants and banks [4]

Core Viewpoint - The company, Chuangshi Technology, is facing significant challenges following the investigation and detention of its controlling shareholder and actual controller, Zhang Gengsheng, which may impact its operations and investor confidence [1][3]. Group 1: Company Announcement - On December 22, Chuangshi Technology announced that it received a "Notice of Filing" and "Notice of Detention" from the Zhou Ping Municipal Supervisory Committee regarding Zhang Gengsheng being investigated [1]. - Zhang Gengsheng resigned as the company's director and chairman on May 17, 2025, and is currently not holding any position within the company [1]. - The company stated that all board members and senior management are performing their duties normally and will continue to monitor the situation and fulfill disclosure obligations as required by law [1]. Group 2: Financial Performance - For the first three quarters of 2025, the company reported revenue of 156 million yuan, a year-on-year increase of 15.45%, while the net profit attributable to shareholders was 15.33 million yuan, a decline of 45.84% [5]. - The company's net profit has been declining for two consecutive years, with figures of 111 million yuan, 81.27 million yuan, and 55.61 million yuan for the years 2022 to 2024, respectively [3]. - As of December 22, the company's stock price was 28.87 yuan per share, with a total market capitalization of approximately 5.911 billion yuan, indicating a stagnant performance throughout the year [5].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 晚间突发！实控人被立案并留置！ 来源：资本秘闻 创识科技表示，张更生已于2025年5月17日辞任公司董事、董事长，目前未在公司担任董事及高管职 务。截至公告日，公司董事及高级管理人员均正常履职，董事会依法履行相关职责。上述事项不会对公 司的生产经营管理情况产生重大负面影响。 责任编辑：杨红卜 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 晚间突发！实控人被立案并留置！ 来源：资本秘闻 创识科技（300941）控股股东、实控人张更生被立案调查并实施留置。 12月22日晚间，创识科技披露公告称，公司于近日收到邹平市监察委员会签发的《立案通知书》和《留 置通知书》，公司控股股东、实际控制人张更生被立案调查并实施留置措施。 创识科技表示，张更生已于2025年5月17日辞任公司董事、董事长，目前未在公司担任董事及高管职 务。截至公告日，公司董事及高级管理人员均正常履职，董事会依法履行相关职责。上述事项不会对公 司的生产经营管理情况产生重大负面影响。 创识科技（300941）控股股东、实控人张更生被立案调查并实施留置。 ...

12月22日晚，创识科技（300941）公告称，公司于近日收到邹平市监察委员会签发的《立案通知书》和 《留置通知书》，公司控股股东、实际控制人张更生被立案调查并实施留置措施。 图片来源：公司公告 公告显示，张更生已于2025年5月17日辞任公司董事、董事长，目前未在公司担任董事及高管职务。截 至公告日，公司董事及高级管理人员均正常履职，董事会依法履行相关职责。 创识科技表示，目前，公司尚未知悉上述事项的进展及结论。公司将持续关注上述事项的后续进展情 况，并按照有关法律、法规的规定和要求，及时履行信息披露义务。 图片来源：公司公告 回溯公告，创识科技于2025年5月17日公告，公司近日收到董事长、董事张更生的辞职报告，张更生因 个人原因申请辞去公司董事、董事长（法定代表人）及专门委员会相关职务。张更生原定任期至2027年 05月16日，辞职后仍在公司任职。 同时，公司董事会同意推举林岚为公司董事长。林岚为公司控股股东及实际控制人，与张更生为配偶关 系。 图片来源：公司公告 创识科技2024年年报显示，公司于2024年11月21日收到控股股东、实际控制人张更生通知，其收到了上 海市浦东新区人民检察院出具的《审查起 ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

创识科技（300941）(300941.SZ)发布公告，公司于近日收到邹平市监察委员会签发的《立案通知书》 和《留置通知书》，公司控股股东、实际控制人张更生先生被立案调查并实施留置措施。张更生先生已 于2025年5月17日辞任公司董事、董事长，目前未在公司担任董事及高管职务。 ...

创识科技(300941.SZ)发布公告，公司于近日收到邹平市监察委员会签发的《立案通知书》和《留置通 知书》，公司控股股东、实际控制人张更生先生被立案调查并实施留置措施。张更生先生已于2025年5 月17日辞任公司董事、董事长，目前未在公司担任董事及高管职务。 ...

格隆汇12月22日丨创识科技(300941.SZ)公布，公司于近日收到邹平市监察委员会签发的《立案通知 书》和《留置通知书》，公司控股股东、实际控制人张更生先生被立案调查并实施留置措施。张更生先 生已于2025年5月17日辞任公司董事、董事长，目前未在公司担任董事及高管职务。截至本公告日，公 司董事及高级管理人员均正常履职，董事会依法履行相关职责。 ...

每经AI快讯，12月22日，创识科技（300941）(300941.SZ)公告称，公司于近日收到邹平市监察委员会 签发的《立案通知书》和《留置通知书》，公司控股股东、实际控制人张更生被立案调查并实施留置措 施。张更生已于2025年5月17日辞任公司董事、董事长，目前未在公司担任董事及高管职务。 ...

截至本公告日，公司董事及高级管理人员均正常履职，董事会依法履行相关 职责。公司拥有完善的治理结构及内部控制机制，将按照《公司法》《上市公司治 理准则》《深圳证券交易所创业板股票上市规则》及《公司章程》等法律法规和相 关制度规范运作，日常经营管理由公司高管团队负责，上述事项不会对公司的生 产经营管理情况产生重大负面影响。 目前，公司尚未知悉上述事项的进展及结论。公司将持续关注上述事项的后 续进展情况，并按照有关法律、法规的规定和要求，及时履行信息披露义务。 公司指定的信息披露媒体为《证券时报》《中国证券报》《上海证券报》《证券 日报》，指定的信息披露网站为巨潮资讯网(www.cninfo.com.cn),公司发布的信息 均以在上述媒体和网站披露的信息为准。敬请广大投资者注意投资风险，理性投 资。 特此公告。 证券代码：300941 证券简称：创识科技 公告编号：2025-044 福建创识科技股份有限公司 关于公司控股股东、实际控制人被采取留置措施的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 福建创识科技股份有限公司（以下简称"公司"）于近日收到邹平市监 ...